Figure 1.
BCR signaling is inhibited by GDC-0853 in CLL patient cells. (A) Representative immunoblot demonstrating the effect of GDC-0853 on BCR signaling. (B-E) Quantification of BCR signaling from 5 patients with CLL using immunoblot densitometry analysis. *P ≤ .05; ***P ≤ .001. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

BCR signaling is inhibited by GDC-0853 in CLL patient cells. (A) Representative immunoblot demonstrating the effect of GDC-0853 on BCR signaling. (B-E) Quantification of BCR signaling from 5 patients with CLL using immunoblot densitometry analysis. *P ≤ .05; ***P ≤ .001. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal